Compare ROCK & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | MYGN |
|---|---|---|
| Founded | 1972 | 1991 |
| Country | United States | United States |
| Employees | 2221 | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 481.6M |
| IPO Year | 1996 | 1996 |
| Metric | ROCK | MYGN |
|---|---|---|
| Price | $41.27 | $4.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 268.1K | ★ 1.5M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,135,501,000.00 | $771,400,000.00 |
| Revenue This Year | $24.00 | $7.19 |
| Revenue Next Year | $34.38 | $5.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $37.80 | $3.76 |
| 52 Week High | $75.08 | $10.32 |
| Indicator | ROCK | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 41.35 |
| Support Level | N/A | $3.93 |
| Resistance Level | $51.86 | $5.63 |
| Average True Range (ATR) | 2.11 | 0.42 |
| MACD | -0.40 | 0.04 |
| Stochastic Oscillator | 25.95 | 21.43 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewables Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.